KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Capital Expenditures (2016 - 2026)

Abbott Laboratories' Capital Expenditures history spans 18 years, with the latest figure at $399.0 million for Q1 2026.

  • On a quarterly basis, Capital Expenditures fell 17.56% to $399.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.1 billion, a 9.03% decrease, with the full-year FY2025 number at $2.2 billion, down 1.63% from a year prior.
  • Capital Expenditures hit $399.0 million in Q1 2026 for Abbott Laboratories, down from $689.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for ABT hit a ceiling of $755.0 million in Q4 2023 and a floor of $321.0 million in Q1 2022.
  • Historically, Capital Expenditures has averaged $515.1 million across 5 years, with a median of $502.0 million in 2025.
  • Biggest five-year swings in Capital Expenditures: decreased 19.14% in 2022 and later skyrocketed 33.77% in 2023.
  • Tracing ABT's Capital Expenditures over 5 years: stood at $610.0 million in 2022, then grew by 23.77% to $755.0 million in 2023, then dropped by 4.64% to $720.0 million in 2024, then dropped by 4.31% to $689.0 million in 2025, then plummeted by 42.09% to $399.0 million in 2026.
  • Business Quant data shows Capital Expenditures for ABT at $399.0 million in Q1 2026, $689.0 million in Q4 2025, and $496.0 million in Q3 2025.